Skip to main content

Table 4 Incidence of comorbidities in the total safety population (n = 492) and among patients taking at least one medication other than interferon beta1-b (n = 246)

From: Clinical characteristics of middle-aged and older patients with MS treated with interferon beta-1b: post-hoc analysis of a 2-year, prospective, international, observational study

Indication(s)a Aged 41–50 years Aged > 50 years
n (%) safety population (n = 334) n (%) comorbid population(n = 161) n (%) safety population(n = 158) n (%) comorbid population(n = 85)
Arterial hypertension 23 (6.9 %) 23 (14.3 %) 19 (12.0 %) 19 (22.4 %)
Diabetes mellitus 5 (1.5 %) 5 (3.1 %) 3 (1.9 %) 3 (3.5 %)
Dyslipidaemia 7 (2.1 %) 7 (4.3 %) 12 (7.6 %) 12 (14.1 %)
Cardiovascular disorders, otherb 10 (3.0 %) 10 (6.2 %) 8 (5.1 %) 8 (9.4 %)
Infectionc 6 (1.8 %) 6 (3.7 %) 2 (1.3 %) 2 (2.4 %)
Malignancies 0 (0.0 %) 0 (0.0 %) 2 (1.3 %) 2 (2.4 %)
Autoimmune disease 13 (3.9 %) 13 (8.1 %) 5 (3.2 %) 5 (5.9 %)
  1. aAdditional medications taken by patients were recorded, and the comorbidity data presented here is derived from the indications for these co-medications.
  2. bThe category of ‘other cardiovascular disorders’ is derived from additional medications with the following indications: anti-aggregation, stroke prevention, thromboembolism, arrhythmia and vascular disease.
  3. cInfection for which patients received antibiotics excluding sexual transmitted disease.